Veglin

Drug Profile

Veglin

Alternative Names: VEGF antisense oligonucleotide - VasGene Therapeutics; VEGF-AS

Latest Information Update: 22 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals; University of Southern California; VasGene Therapeutics
  • Developer VasGene Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Kaposi's sarcoma; Mesothelioma; Renal cancer

Most Recent Events

  • 22 Jan 2016 Discontinued - Phase-I for Cancer in USA (IV)
  • 22 Jan 2016 Discontinued - Phase-I for Kaposi's sarcoma in USA (unspecified route)
  • 22 Jan 2016 Discontinued - Phase-I for Mesothelioma (Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top